INNOVITA, the only In-vitro diagnostic company in Hebei Province, won the national honor

In September 2020, Innovita (Tangshan) Biotechnology Co., Ltd.(INNOVITA)was commended as an advanced group in the nation’s fight against the Covid-19 epidemic. This is the only In-vitro diagnostic company in Hebei Province to receive this honor.

“After the outbreak of the Covid-19 epidemic, Innovita (Tangshan) Biotechnology Co., Ltd. immediately acted to take advantage of the technical advantages of focusing on diagnostic kits for respiratory infectious diseases for many years, and urgently deploy elites to carry out scientific research.” INNOVITA introduced.

INNOVITA has a scientific research team composed of PhDs and senior professional personnel. All members of the R&D team gave up their holidays and returned to the company’s R&D center from various places, returned to work as soon as possible, and devoted themselves to the research and development of Covid-19 detection reagents. Racing against time, racing against the rapidly spreading virus, relying on the technical advantages of respiratory diagnostic reagents, risking being infected by the virus, and overcoming difficulties from raw material screening and process optimization, to clinical verification, INNOVITA successfully developed 2019-nCoV Antibody Test Kit.

On February 9, 2020, the product passed the expert defense of the National Food and Drug Administration. On February 11, it was identified as a national key research project by the Ministry of Science and Technology. On February 22, INNOVITA developed a new type of 2019-nCoV antibody test kit, which stood out from the many declared products in the country and became one of the first two companies in the country to obtain the registration certificate for Covid-19 antibody test reagents. Famous experts recognized the diagnostic effect of INNOVITA 2019-nCov antibody test kit.

Unlike the well-known nucleic acid detection reagents for the Covid-19, INNOVITA has developed a new Covid-19 antibody detection reagent. In the test process, the lgM antibody in the patient can be detected, and the lgM antibody can be detected on the 7th day of the patient’s infection or the 3rd day of the onset, providing a more comprehensive reference for clinical diagnosis.

Post time: Oct-18-2021